Ascletis Pharma
01672
Performance
About Ascletis Pharma
Ascletis Pharma is a biotechnology company focused on the development and commercialization of therapeutics for metabolic and related diseases. It employs proprietary AI-assisted structure-based drug discovery (AISBDD) and an Ultra-Long-Acting Platform (ULAP) along with Peptide Oral Transport ENhancement Technology (POTENT) to create both small molecules and peptides, including lead programs for chronic weight management. The company conducts research and development with in-house drug candidates such as ASC30, ASC36, ASC35, and ASC37, and is listed on the Hong Kong Stock Exchange (1672.HK).
Recent News
Ascletis Announces Positive Topline Results From U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity
Nine Biotech Companies that Could Revolutionize Obesity Treatments
Ascletis Completes Enrollment in U.S. Phase‑II Trial of Oral GLP‑1 Agonist ASC30
Recent Deals
No recent deals for this company.